Worcester State University COVID vaccination clinic resumes use of Johnson & Johnson vaccine

Worcester State University COVID vaccination clinic resumes use of Johnson & Johnson vaccine

"Therefore, the Danish Health Authority will continue the Danish mass vaccination programme against Covid-19 without the Covid-19 vaccine from Johnson & Johnson", it added.

There are now four vaccine types being used in France: Those of AstraZeneca, Johnson & Johnson, Pfizer-BioNTech and Moderna.

France began administering the J&J vaccine on 24 April.

NACI also recommended that provinces use the J&J vaccine on populations that may have trouble booking a second dose if they were given a different vaccine.

The European Medicines Agency (EMA) has said of the AstraZeneca Covid-19 vaccine that the benefits "outweigh its risks in adults of all age groups; however, very rare cases of blood clots with low blood platelets have occurred following vaccination". These all use the virus' genetic code to promote an antibody response, but enter the cells differently.

The FDA halted production of the vaccines at a USA manufacturing plant owned by Emergent BioSolutions earlier this month as it investigates an error that led to millions of doses being ruined in March.

Canada has already received its first 300,000 dose shipment of the J&J vaccine but it has not been distributed after Health Canada learned some of the vaccines were made at a Maryland facility that botched the earlier production of 15 million doses.

But Danish health officials said the current favourable epidemiological situation in the Scandinavian country meant it could do without the J&J jab, and would rely only on the Pfizer/BioNTech and Moderna vaccines.

The Emergent Biosolutions facility in Baltimore was recently cited by the FDA for violations including cleaning and sterilization failures, the potential for cross-contamination and failure to follow required protocols.

Denmark removed the single-dose Johnson & Johnson COVID-19 shot from its vaccination program to investigate reports of rare but potentially unsafe blood clots, health authorities said Monday.

As a result, Health Canada won't release the doses until it's satisfied they meet quality, safety and efficacy standards.

Related Articles